Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA meeting on epinephrine

This article was originally published in The Tan Sheet

Executive Summary

FDA announces a Dec. 5 public meeting to solicit comments on a proposed rule to amend the agency's regulation on the use of ozone-depleting substances in self-pressurized containers to "remove the essential-use designation for oral pressurized metered-dose inhalers containing epinephrine." In addition, the comment period on the proposed rule published in September is being extended to Dec. 19, FDA says (1"The Tan Sheet" Sept. 24, 2007, p. 7). Meeting attendees must register by Nov. 23, according to the agency...
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS101088

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel